profit from every $100 of sales.
$0$100
Aclaris Therapeutics
$4.34+4.58% today
+88.7% in 1 year
1-year low $2.301-year high $6.53
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Aclaris Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $29.8 million in 2022 to $7.83 million in 2025, with -$64.9 million of profit last year.
SalesProfit
Aclaris Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Aclaris Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Aclaris Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 30 | 31 | 19 | 8 | |
| 18 | 13 | 3 | 1 | |
| -85 | -116 | -53 | -74 | |
| -84 | -115 | -52 | -74 | |
| -87 | -88 | -132 | -65 | |
| -1.33 | -1.27 | -1.71 | -0.53 | |
| 59.8% | 42.1% | 17.4% | 6.9% | |
| -286.2% | -372.2% | -280.6% | -946.5% | |
| -292.1% | -283.1% | -705.5% | -829.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 255 | 197 | 220 | 160 |
| Cash | 45 | 40 | 25 | 20 |
| Total debt | 1 | 0 | – | – |
| Total liabilities | 57 | 40 | 65 | 57 |
| 198 | 157 | 156 | 103 | |
| 65 | 70 | 77 | 123 | |
| -33.9% | -58.3% | -26.7% | -56.8% | |
| -44.0% | -56.3% | -84.9% | -63.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -68 | -78 | -20 | -47 | |
| 1 | 1 | 36 | 0 | |
| -68 | -80 | -56 | -47 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 15 | 21 | 11 | 12 |
Valuation
- –
- –
- –
- 4.1×
- 88.0×
- –
- –
- -6.9%
- -9.4%
- 0.0%
Profitability
- 6.9%
- -946.5%
- -829.6%
- -873.5%
- -46.8%
- -58.5%
- -55.9%
- -35.1%
- -47.0%
- 677.9%
Growth
- −35.9%
- –
- −133.3%
- –
- +21.3%
Financial health
- -0.3×
- 0.01
- 1.0%
- –
- 4.03
- 4.03
- 0.04
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 8%of 958
Bottom 3%of 889
Bottom 14%of 987
What analysts expect
- Average price target
- $10.00
- Range
- $10.00 – $10.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.15 | -0.16 | +6.3% |
| Feb 26, 2026 | -0.16 | -0.15 | −6.7% |
| Nov 6, 2025 | -0.12 | -0.13 | +7.7% |
| Aug 7, 2025 | -0.13 | -0.13 | +0.0% |
| May 8, 2025 | -0.12 | -0.17 | +29.4% |
| Feb 27, 2025 | -0.10 | -0.09 | −11.1% |
| Nov 6, 2024 | -0.11 | -0.08 | −37.5% |
| Aug 7, 2024 | -0.15 | -0.19 | +21.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
40No pass
Philip Fisher
28No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
26No pass
Terry Smith
23No pass
Questions about Aclaris Therapeutics
Is Aclaris Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aclaris Therapeutics AI analysis
What does Aclaris Therapeutics do?
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. It is in Biotechnology.
Does Aclaris Therapeutics pay a dividend?
No. Aclaris Therapeutics does not pay a dividend at the moment.
Is Aclaris Therapeutics stock halal?
Yes. Aclaris Therapeutics passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Aclaris Therapeutics stock done over the past year?
Up 88.7% over the past twelve months, to $4.34. It traded between $2.30 and $6.53 and is 33.6% below its high.
Who are Aclaris Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Aclaris Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.